Compare Stocks: ACET, ADMA, STRO, and ABEO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$6.00	$6.44	$4.00 ▼ $7.65	$343.08M	1.33	1.58 million shs	866,502 shs
ACET Adicet Bio	$9.59	$8.72	$6.01 ▼ $17.44	$89.77M	1.58	89,168 shs	44,518 shs
ADMA ADMA Biologics	$9.62	$9.15	$7.21 ▼ $20.46	$2.15B	0.78	1.82 million shs	1.40 million shs
STRO Sutro Biopharma	$20.07	$24.59	$7.15 ▼ $43.85	$332.76M	1.48	279,052 shs	124,764 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	0.00%	+1.35%	-17.13%	+11.52%	-12.92%
ACET Adicet Bio	0.00%	+5.85%	+20.18%	+32.83%	-16.79%
ADMA ADMA Biologics	0.00%	+3.00%	-2.83%	+19.35%	-42.98%
STRO Sutro Biopharma	0.00%	-1.86%	-20.92%	-21.02%	+89.34%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$6.00	$6.44	$4.00 ▼ $7.65	$343.08M	1.33	1.58 million shs	866,502 shs
ACET Adicet Bio	$9.59	$8.72	$6.01 ▼ $17.44	$89.77M	1.58	89,168 shs	44,518 shs
ADMA ADMA Biologics	$9.62	$9.15	$7.21 ▼ $20.46	$2.15B	0.78	1.82 million shs	1.40 million shs
STRO Sutro Biopharma	$20.07	$24.59	$7.15 ▼ $43.85	$332.76M	1.48	279,052 shs	124,764 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	0.00%	+1.35%	-17.13%	+11.52%	-12.92%
ACET Adicet Bio	0.00%	+5.85%	+20.18%	+32.83%	-16.79%
ADMA ADMA Biologics	0.00%	+3.00%	-2.83%	+19.35%	-42.98%
STRO Sutro Biopharma	0.00%	-1.86%	-20.92%	-21.02%	+89.34%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	2.33	Hold	$19.33	222.22% Upside
ACET Adicet Bio	2.88	Moderate Buy	$46.80	388.01% Upside
ADMA ADMA Biologics	2.50	Moderate Buy	$18.67	94.04% Upside
STRO Sutro Biopharma	3.00	Buy	$47.30	135.68% Upside

Current Analyst Ratings Breakdown

Latest ACET, ADMA, STRO, and ABEO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/1/2026	ACET Adicet Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	ACET Adicet Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/17/2026	ABEO Abeona Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/14/2026	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00 ➝ $21.00
8/13/2026	STRO Sutro Biopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/13/2026	STRO Sutro Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$41.00 ➝ $34.00
8/13/2026	STRO Sutro Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$60.00
8/7/2026	STRO Sutro Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$48.00
8/6/2026	ACET Adicet Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00 ➝ $90.00
8/5/2026	STRO Sutro Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$5.82M	58.95	N/A	N/A	$2.94 per share	2.04
ACET Adicet Bio	N/A	N/A	N/A	N/A	$16.62 per share	N/A
ADMA ADMA Biologics	$510.17M	4.22	$0.65 per share	14.71	$2.01 per share	4.79
STRO Sutro Biopharma	$102.48M	3.25	N/A	N/A	($15.43) per share	-1.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	$71.18M	-$1.09	N/A	N/A	N/A	N/A	-41.69%	-30.36%	11/11/2026 (Estimated)
ACET Adicet Bio	-$116.80M	-$11.45	N/A	N/A	N/A	N/A	-74.90%	-60.87%	11/4/2026 (Estimated)
ADMA ADMA Biologics	$146.93M	$0.70	13.74	11.32	N/A	32.98%	40.17%	26.97%	11/4/2026 (Estimated)
STRO Sutro Biopharma	-$191.09M	-$11.97	N/A	N/A	N/A	-395.25%	N/A	-88.12%	11/5/2026 (Estimated)

Latest ACET, ADMA, STRO, and ABEO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ABEO Abeona Therapeutics	-$0.2317	-$0.35	-$0.1183	-$0.35	$12.24 million	$11.38 million
8/12/2026	Q2 2026	STRO Sutro Biopharma	-$2.19	-$2.33	-$0.14	-$2.33	$11.96 million	$9.84 million
8/5/2026	Q2 2026	ACET Adicet Bio	-$1.69	-$1.99	-$0.30	-$1.99	N/A	N/A
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
ACET Adicet Bio	$0.04	0.42%	N/A	N/A	N/A
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.01	6.63	6.40
ACET Adicet Bio	0.01	6.71	6.71
ADMA ADMA Biologics	0.49	6.97	3.81
STRO Sutro Biopharma	N/A	3.32	3.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
ACET Adicet Bio	83.89%
ADMA ADMA Biologics	75.68%
STRO Sutro Biopharma	96.99%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	7.10%
ACET Adicet Bio	3.40%
ADMA ADMA Biologics	3.90%
STRO Sutro Biopharma	1.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	57.18 million	53.12 million	Optionable
ACET Adicet Bio	90	9.36 million	9.04 million	Optionable
ADMA ADMA Biologics	530	223.99 million	215.25 million	Optionable
STRO Sutro Biopharma	240	16.58 million	16.28 million	Optionable

ACET, ADMA, STRO, and ABEO Headlines

Recent News About These Companies

Seven Fleet Capital Management LP Makes New Investment in Sutro Biopharma, Inc. $STRO

September 5 at 5:44 AM | marketbeat.com

Merck & Co. Inc. Invests $9.04 Billion in Sutro Biopharma, Inc. $STRO

August 18, 2026 | marketbeat.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of "Buy" by Analysts

August 15, 2026 | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)

August 14, 2026 | theglobeandmail.com

Sutro Biopharma Q3 EPS Forecast Reduced by HC Wainwright

August 14, 2026 | marketbeat.com

Sutro Biopharma (NASDAQ:STRO) Price Target Lowered to $34.00 at Citizens Jmp

August 13, 2026 | marketbeat.com

Sutro Biopharma (NASDAQ:STRO) Earns Outperform Rating from Wedbush

August 13, 2026 | marketbeat.com

STRO stock plummets 15% — what drove the selloff?

August 12, 2026 | msn.com

Why is Sutro Biopharma Stock Falling On Wednesday?

August 12, 2026 | benzinga.com

Sutro Biopharma (NASDAQ:STRO) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS

August 12, 2026 | marketbeat.com

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

August 12, 2026 | globenewswire.com

News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts

May 28, 2026 | finance.yahoo.com

US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results

May 17, 2026 | finance.yahoo.com

Wedbush upgrades Sutro Biopharma (STRO)

May 16, 2026 | msn.com

Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

May 14, 2026 | globenewswire.com

Citizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead Program

May 1, 2026 | insidermonkey.com

Mizuho initiates coverage of Sutro Biopharma (STRO) with outperform recommendation

May 1, 2026 | msn.com

Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell

May 1, 2026 | seekingalpha.com

Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now

April 29, 2026 | finance.yahoo.com

Sutro Biopharma, Inc. (STRO) Presents at AACR Annual Meeting 2026 - Slideshow

April 24, 2026 | seekingalpha.com

Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

April 19, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ACET, ADMA, STRO, and ABEO Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$6.00 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Adicet Bio NASDAQ:ACET

$9.59 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

ADMA Biologics NASDAQ:ADMA

$9.62 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Sutro Biopharma NASDAQ:STRO

$20.07 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACET, ADMA, STRO, and ABEO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACET, ADMA, STRO, and ABEO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACET, ADMA, STRO, and ABEO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACET, ADMA, STRO, and ABEO Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

Adicet Bio NASDAQ:ACET

ADMA Biologics NASDAQ:ADMA

Sutro Biopharma NASDAQ:STRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACET, ADMA, STRO, and ABEO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACET, ADMA, STRO, and ABEO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACET, ADMA, STRO, and ABEO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACET, ADMA, STRO, and ABEO Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

Adicet Bio NASDAQ:ACET

ADMA Biologics NASDAQ:ADMA

Sutro Biopharma NASDAQ:STRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools